Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma
Kinase inhibitor sorafenib is the most widely used drug for advanced HCC clinical treatment nowadays. However, sorafenib administration is only effective for a small portion of HCC patients, and the majority develop sorafenib-resistance during treatment. Thus, it is urgent to discover the endogenous...
Saved in:
Published in | Biochimica et biophysica acta. General subjects Vol. 1862; no. 4; pp. 1017 - 1030 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.04.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!